Buy Yupelri (revefenacin) Online For Sale
DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease
MANUFACTURER: Theravance Biopharma
MEDICINE APPROVED BY:
Food and Drug Administration (FDA)
Yupelri (revefenacin) is a medication approved by the Food and Drug Administration (FDA) for the treatment of patients with COPD. It improves lung function by increasing forced expiratory volume in 1 second (FEV1) and reducing symptoms such as coughing and shortness of breath.
What is Yupelri (revefenacin) for?
Yupelri (revefenacin) is a medication used to treat chronic obstructive pulmonary disease (COPD) by functioning as a long-acting muscarinic antagonist (LAMA). It is formulated as a vial containing 175 μg/3 mL revefenacin and can be administered with a standard jet nebulizer.
How does Yupelri (revefenacin) work?
Yupelri (revefenacin) contains revefenacin, which is a long-acting muscarinic antagonist (LAMA) or an anticholinergic agent. It works by binding to a type of receptor called the muscarinic receptor in the airways. This action blocks the activity of acetylcholine that maintains airway contraction in patients with COPD. By blocking these muscarinic receptors, bronchodilation occurs, which means the smooth muscles in the airways relax, leading to the widening of the lungs’ air passages. Overall, this medication helps to reduce the symptoms of COPD, including shortness of breath, wheezing, and coughing. It is important to note that Yupelri is prescribed and should only be used under the supervision of a healthcare professional.
How is Yupelri (revefenacin) taken?
Yupelri (revefenacin) is an inhaled medication that should be used once daily with a standard jet nebulizer connected to an air compressor. The recommended dose is one 175 mcg vial (3 mL). Before using Yupelri, it is important to carefully read the instructions provided by the healthcare provider.
To take Yupelri, attach the mouthpiece of the nebulizer to the drug chamber. Open the vial and carefully pour the contents into the chamber of the nebulizer. Connect the nebulizer to the air compressor and turn it on. Breathe in the medication through the mouthpiece until the mist disappears, which takes about 8 minutes. After inhalation, clean the nebulizer as per the instructions provided by the healthcare provider.
It is essential to use Yupelri precisely as directed by the healthcare provider. Do not increase or decrease the dose without consulting the healthcare provider. If a dose is missed, use it as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule.
Are there any known side effects of Yupelri (revefenacin)?
Yes, there are known side effects of Yupelri (revefenacin). The most common side effects reported by patients who use Yupelri are:
– runny or stuffy nose
– sore throat
– back pain
In some rare cases, more severe side effects can occur, including:
– an allergic reaction, such as swelling in the face, lips, tongue, or throat
– difficulty breathing and wheezing
– chest pain
– fast or abnormal heartbeats
– high blood pressure
– urinary retention
– blurred vision, eye pain, or seeing halos around lights
If you experience any of these severe side effects, contact your healthcare provider immediately. It is also important to report any other unusual symptoms to your healthcare provider.
Yupelri (revefenacin) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with COPD, based on data from two phase 3 trials – Study 0126 (NCT02459080) and Study 0127 (NCT02512510). These were randomized, double-blind, placebo-controlled, parallel-group studies involving 1,229 participants with COPD who received Yupelri 88 μg, revefenacin 175 μg, or placebo once daily for 12 weeks. Lung function, measured by 24-hour trough forced expiratory volume in 1 second (FEV1), was the primary endpoint. After 12 weeks, Yupelri significantly improved lung function compared to placebo, with an increase in FEV1 of 79 mL (low dose) and 146 mL (high dose) in Study 0126, and 160 mL (low dose) and 147 mL (high dose) in Study 0127. For more detailed information about the safety and effectiveness of Yupelri, please refer to the summary of product characteristics in the resource section.
175 μg/3 mL